Haemonetics Co. (NYSE:HAE) Receives $97.89 Average PT from Brokerages

Shares of Haemonetics Co. (NYSE:HAE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $97.89.

HAE has been the topic of several analyst reports. Barrington Research lowered their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Raymond James reaffirmed a "strong-buy" rating and issued a $105.00 price objective (down previously from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. JMP Securities reaffirmed a "market outperform" rating and issued a $100.00 price objective on shares of Haemonetics in a research note on Tuesday, May 20th. Needham & Company LLC lowered their price objective on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Bank of America cut shares of Haemonetics from a "neutral" rating to an "underperform" rating and lowered their price objective for the stock from $95.00 to $68.00 in a research note on Friday, February 7th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Boston Trust Walden Corp lifted its position in shares of Haemonetics by 13.1% in the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock worth $71,500,000 after purchasing an additional 106,114 shares in the last quarter. Empowered Funds LLC purchased a new stake in shares of Haemonetics in the fourth quarter worth approximately $319,000. Pacer Advisors Inc. grew its holdings in shares of Haemonetics by 36.1% during the 4th quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock valued at $789,000 after acquiring an additional 2,680 shares in the last quarter. Norges Bank purchased a new position in shares of Haemonetics during the 4th quarter valued at $32,803,000. Finally, Voya Investment Management LLC grew its holdings in shares of Haemonetics by 820.5% during the 4th quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier's stock valued at $24,748,000 after acquiring an additional 282,521 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Stock Performance

Shares of HAE traded down $0.06 during mid-day trading on Tuesday, hitting $66.10. The stock had a trading volume of 356,407 shares, compared to its average volume of 683,601. The company has a market cap of $3.32 billion, a PE ratio of 26.02, a PEG ratio of 1.11 and a beta of 0.32. The company's fifty day simple moving average is $63.13 and its two-hundred day simple moving average is $70.89. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics has a fifty-two week low of $55.30 and a fifty-two week high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. The company had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. During the same period in the previous year, the firm posted $0.90 earnings per share. Haemonetics's quarterly revenue was down 3.5% compared to the same quarter last year. On average, equities analysts expect that Haemonetics will post 4.55 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.